scispace - formally typeset
Open AccessJournal ArticleDOI

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

TLDR
Treatment with alpelisib–fulvestrant prolonged progression‐free survival among patients with PIK3CA‐mutated, HR‐positive, HER2‐negative advanced breast cancer who had received endocrine therapy previously.
Abstract
Background PIK3CA mutations occur in approximately 40% of patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer. The PI3Kα-sp...

read more

Citations
More filters
Journal ArticleDOI

A view on drug resistance in cancer

TL;DR: A reductionist approach is taken to define and separate the key determinants of drug resistance, which include tumour burden and growth kinetics; tumour heterogeneity; physical barriers; the immune system and the microenvironment; undruggable cancer drivers; and the many consequences of applying therapeutic pressures.
Journal ArticleDOI

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

TL;DR: The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.
Journal ArticleDOI

The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism

TL;DR: The PI3K–AKT signalling network is discussed and its control of cancer cell metabolism through both direct and indirect regulation of nutrient transport and metabolic enzymes, thereby connecting oncogenic signalling and metabolic reprogramming to support cancer cell survival and proliferation.
Journal ArticleDOI

Liquid biopsy enters the clinic - implementation issues and future challenges.

TL;DR: In this article, the authors discuss key issues and gaps in technology, clinical trial methodologies and logistics for the eventual integration of liquid biopsy into the clinical workflow, and discuss the potential applications of this technology in cancer screening and diagnosis.
References
More filters
Journal ArticleDOI

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

TL;DR: This ESO-ESMO ABC 5 Clinical Practice Guideline provides key recommendations for managing advanced breast cancer patients, and provides updates on managing patients with all breast cancer subtypes, LABC, follow-up, palliative and supportive care.
Journal ArticleDOI

US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status

TL;DR: In the future, SEER data can be used to monitor clinical outcomes in women diagnosed with different molecular subtypes of breast cancer for a large portion of the US population.
Journal ArticleDOI

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer

TL;DR: The data suggest that upon adaptation to hormone deprivation, breast cancer cells rely heavily on PI3K signaling, and imply that acquired resistance to endocrine therapy in breast cancer may be abrogated by combination therapies targeting both ER andPI3K pathways.
Related Papers (5)

Comprehensive molecular portraits of human breast tumours

Daniel C. Koboldt, +355 more
- 04 Oct 2012 -